Ethic Inc. Purchases 3,821 Shares of Gilead Sciences, Inc. $GILD

Ethic Inc. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,093 shares of the biopharmaceutical company’s stock after purchasing an additional 3,821 shares during the quarter. Ethic Inc.’s holdings in Gilead Sciences were worth $8,311,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences during the first quarter valued at $25,000. Activest Wealth Management lifted its position in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the second quarter valued at $27,000. Goodman Advisory Group LLC purchased a new position in Gilead Sciences during the first quarter valued at $29,000. Finally, Colonial Trust Advisors lifted its position in Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on GILD. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a research report on Tuesday, August 19th. Finally, The Goldman Sachs Group lifted their price target on Gilead Sciences from $105.00 to $108.00 and gave the stock a “neutral” rating in a research report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $121.14.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares in the company, valued at $66,013,726.98. The trade was a 1.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,500 shares of company stock worth $8,281,540 in the last three months. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $121.46 on Thursday. Gilead Sciences, Inc. has a fifty-two week low of $86.08 and a fifty-two week high of $124.61. The business has a 50-day simple moving average of $115.38 and a two-hundred day simple moving average of $110.78. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market cap of $150.71 billion, a price-to-earnings ratio of 24.20, a price-to-earnings-growth ratio of 0.85 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm earned $2.01 EPS. Gilead Sciences’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s payout ratio is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.